Altay Therapeutics is developing small molecule therapies that target disease-causing transcription factors to treat chronic inflammatory conditions. By focusing on these specific molecular targets, the company aims to provide effective treatment options for patients suffering from persistent inflammation.
Funding
$3.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CDSFTVFounders
Product
Problem
Chronic inflammatory conditions are often driven by dysregulation of transcription factors, leading to persistent inflammation and tissue damage. Current treatments often have limited efficacy or significant side effects due to their broad mechanisms of action.
Solution
Altay Therapeutics is developing small molecule therapies that selectively target disease-causing transcription factors involved in chronic inflammatory conditions. By modulating the activity of these specific molecular targets, Altay aims to disrupt the inflammatory cascade at its source, offering a more targeted and effective approach to treatment. This precision approach has the potential to reduce off-target effects and improve patient outcomes compared to traditional therapies. Altay's pipeline focuses on identifying and developing novel compounds that can selectively inhibit or modulate the activity of key transcription factors implicated in various inflammatory diseases.
Target Audience
The primary target audience includes patients suffering from chronic inflammatory conditions, as well as physicians and specialists seeking more effective and targeted treatment options.
Features
- Small molecule therapeutics designed for targeted modulation of transcription factor activity.
- Focus on disease-causing transcription factors implicated in chronic inflammatory conditions.
- Development of novel compounds with improved selectivity and reduced off-target effects.
- Pipeline targeting a range of inflammatory diseases.